June 6, 2008 - Dubai, UAE
MPR Inc. in collaboration with Julphar Pharmaceutical Industries, a UAE based Pharmaceutical Company, launches several collaboration projects to undertake the development and commercialization of several health products developed by USA based companies. The products are in the treatments of diseases in diabetes, cancer and CNS.
This project leverages MPR Inc. expertise in drug development and its strong resources and experience in financial and risk management. Large financial institutions are involved in the development and negotiation, including:
Abu Dhabi Investment Authority, a UAE based investment and development institution
Global Investment House, a Kuwaiti based investment and development institution
Shuaa Capital, a GCC based investment and commercial bank
Standard Charter Bank, an international investment and commercial bank
In developing the deals, MPR assembled the initial portfolio using innovative methodology of technology options (Real Options Valuations, ROV): a stochastic optimization model of R&D portfolio management using real options for project selections. The methodology views products development as a series of continuation/abandonment options. The methodology could be used by different approaches. The approach used in here is based on a limited budget for the portfolio selection assumed by Series A available funds. There are several literature sources about this tool. Please do not hesitate to request more details.